Achilles Therapeutics has raised more than $175m in its initial public offering on the Nasdaq Global Select Market.
Achilles Therapeutics, a UK-based cancer immunotherapy developer spun out from University College London and Francis Crick Institute, has gone public following an initial public offering that raised more than $175m.
The spinout issued 9.75 million American Depositary Shares (ADSs) – representing the same number of ordinary stock – priced at $18 and listed on the Nasdaq Global Select Market under the ticker symbol ACHL.
Achilles is working on personalised T cell cancer therapies for solid tumours. Proceeds…
